title: Concurrent chemoradiotherapy with nedaplatin plus paclitaxel or fluorouracil for locoregionally advanced nasopharyngeal carcinoma: Survival and toxicity.
abstract: BACKGROUND
  The purpose of this study was to review the survival and toxicity in patients with locoregionally advanced nasopharyngeal carcinoma (NPC) treated with intensity-modulated radiation therapy (IMRT) and concurrent nedaplatin plus paclitaxel or fluorouracil (NP or NF).
  
  
  METHODS
  A total of 155 patients with locoregionally advanced NPC seen at our institution between January 2008 and December 2010 were retrospectively reviewed. Seventy-nine cases (51%) were treated with IMRT and concurrent NP chemotherapy, and 76 cases (49%) were treated with IMRT and concurrent NF regimen. Survival and toxicity were reported.
  
  
  RESULTS
  The 3-year locoregional relapse-free survival, distant metastasis-free survival, progression-free survival (PFS), and overall survival (OS) rates were 90.3% and 87.8%, 79.7% and 81.1%, 77.3% and 71.1%, and 81.6% and 83.7% for the NF and NP group, respectively. The results were comparable to that of the cisplatin-based regimens. Acute and late toxicities were acceptable.
  
  
  CONCLUSIONS
  IMRT with concurrent nedaplatin-based chemotherapy achieved comparable survival with acceptable toxicity to those of the cisplatin-based regimens in the treatment of locoregionally advanced NPC.
authors.affiliation: Department of Radiation Oncology, Jiangsu Cancer Hospital Affiliated with Nanjing Medical University, Nanjing, China.
authors.forename: Jianhua
authors.initials: J
authors.lastname: Xu
authors.forename: Xia
authors.initials: X
authors.lastname: He
authors.forename: Kong
authors.initials: K
authors.lastname: Cheng
authors.forename: Wenjie
authors.initials: W
authors.lastname: Guo
authors.forename: Xiuhua
authors.initials: X
authors.lastname: Bian
authors.forename: Xuesong
authors.initials: X
authors.lastname: Jiang
authors.forename: Lanfang
authors.initials: L
authors.lastname: Zhang
authors.forename: Shengfu
authors.initials: S
authors.lastname: Huang
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D059248:Chemoradiotherapy; D018450:Disease Progression; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009303:Nasopharyngeal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D009944:Organoplatinum Compounds / Q000008:administration & dosage*; D017239:Paclitaxel / Q000008:administration & dosage*; D011879:Radiotherapy Dosage; D050397:Radiotherapy, Intensity-Modulated
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C053989:nedaplatin; D017239:Paclitaxel; D005472:Fluorouracil
keywords: chemoradiation; intensity-modulated radiation therapy (IMRT); locoregionally advanced nasopharyngeal carcinoma (NPC); nedaplatin; toxicity